Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

GlaxoSmithKline PLC (NYSE:GSK)

43.91
Delayed Data
As of Jun 27
 -0.16 / -0.36%
Today’s Change
37.20
Today|||52-Week Range
45.58
+14.02%
Year-to-Date
Top Analyst Reports for Alphabet, Berkshire Hathaway & Nike
Jun 27 / Zacks.com - Paid Partner Content
VBI Vaccines Just Took a Major Step Forward in Its HBV Program
Jun 21 / GuruFocus News - Paid Partner Content
Vaccine Small-Cap Just Took a Big Step Forward
Jun 26 / GuruFocus News - Paid Partner Content
Novartis (NVS) Biosimilar of MabThera Approved in the EU
Jun 19 / Zacks.com - Paid Partner Content
Novartis Cardiovascular Drug Positive, NSCLC Drug Approved
Jun 26 / Zacks.com - Paid Partner Content
GlaxoSmithKline's Benlysta Positive in Continuation Trial
Jun 19 / Zacks.com - Paid Partner Content
Hikma Shakes Up U.S. Operations After FDA Disappointment; CEO Said Darwazah to Lead G...
Jun 26 / TheStreet.com - Paid Partner Content
Should Value Investors Pick GlaxoSmithKline (GSK) Stock Now?
Jun 16 / Zacks.com - Paid Partner Content
Glaxo's (GSK) Shingles Candidate Phase III Data Positive
Jun 22 / Zacks.com - Paid Partner Content
Puma (PBYI) Stock Surges as Neratinib Nears FDA Approval
Jun 15 / Zacks.com - Paid Partner Content
Novartis Announces Positive Results for Cardiovascular Drug
Jun 22 / Zacks.com - Paid Partner Content